J
Jesse J. Jung
Researcher at University of California, San Francisco
Publications - 73
Citations - 1975
Jesse J. Jung is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Visual acuity & Macular degeneration. The author has an hindex of 21, co-authored 65 publications receiving 1607 citations. Previous affiliations of Jesse J. Jung include University of Southern California & New York University.
Papers
More filters
Journal ArticleDOI
The Incidence of Neovascular Subtypes in Newly Diagnosed Neovascular Age-Related Macular Degeneration
Jesse J. Jung,Christine Y. Chen,Sarah Mrejen,Roberto Gallego-Pinazo,Luna Xu,Marcela Marsiglia,Marcela Marsiglia,Sucharita Boddu,K. Bailey Freund +8 more
TL;DR: With both FA-alone and FA+OCT grading, a higher incidence of type 3 NV in eyes with newly diagnosed neovascular AMD than that reported in prior studies is found.
Journal ArticleDOI
Deep learning versus human graders for classifying diabetic retinopathy severity in a nationwide screening program.
Paisan Ruamviboonsuk,Jonathan Krause,Peranut Chotcomwongse,Rory Sayres,Rajiv Raman,Kasumi Widner,Bilson J. L. Campana,Sonia Phene,Kornwipa Hemarat,Mongkol Tadarati,Sukhum Silpa-archa,Jirawut Limwattanayingyong,Chetan Rao,Oscar Kuruvilla,Jesse J. Jung,Jeffrey Tan,Surapong Orprayoon,Chawawat Kangwanwongpaisan,Ramase Sukumalpaiboon,Chainarong Luengchaichawang,Jitumporn Fuangkaew,Pipat Kongsap,Lamyong Chualinpha,Sarawuth Saree,Srirut Kawinpanitan,Korntip Mitvongsa,Siriporn Lawanasakol,Chaiyasit Thepchatri,Lalita Wongpichedchai,Greg S. Corrado,Lily Peng,Dale R. Webster +31 more
TL;DR: Across different severity levels of DR for determining referable disease, deep learning significantly reduced the false negative rate at the cost of slightly higher false positive rates (2%).
Journal ArticleDOI
Effect on Intraocular Pressure in Patients Receiving Unilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Quan V Hoang,Luis S. Mendonca,Kara E. Della Torre,Jesse J. Jung,Angela J. Tsuang,K. Bailey Freund +5 more
TL;DR: A greater number of intravitreal anti-vasular endothelial growth factor injections is associated with an increased risk for IOP elevation >5 mmHg on ≥2 consecutive visits in eyes with neovascular AMD receiving intravItreal ranbizumab and/or bevacizumab.
Journal ArticleDOI
Type 3 neovascularization: Evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography
Aaron Nagiel,David Sarraf,Srinivas R. Sadda,Srinivas R. Sadda,Richard F. Spaide,Jesse J. Jung,Kavita V. Bhavsar,Hossein Ameri,Giuseppe Querques,K. Bailey Freund +9 more
TL;DR: In some eyes with age-related macular degeneration, the earliest sign of Type 3 neovascularization is punctate hyperreflective foci above the external limiting membrane, and the mature Type 3 lesions and associated serous pigment epithelial detachments are highly responsive to anti-vascular endothelial growth factor therapy.
Journal ArticleDOI
A Comparison Between Optical Coherence Tomography Angiography and Fluorescein Angiography for the Imaging of Type 1 Neovascularization
Maiko Inoue,Maiko Inoue,Jesse J. Jung,Chandrakumar Balaratnasingam,Kunal K. Dansingani,Elona Dhrami-Gavazi,Elona Dhrami-Gavazi,Mihoko Suzuki,Talisa E de Carlo,Talisa E de Carlo,Abtin Shahlaee,Michael A. Klufas,Adil El Maftouhi,Jay S. Duker,Allen C. Ho,Maddalena Quaranta-El Maftouhi,David Sarraf,K. Bailey Freund,K. Bailey Freund +18 more
TL;DR: En face OCTA and structural OCT showed better detection of type 1 NV than either FA alone or en face OCT a alone and may be a useful way to noninvasively diagnose and monitor the treatment of type 2 neovascularization.